Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.31 |
| ▸ | FPR3 | P25089 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL98924 | 0.88 | CHRNB2 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4CA14 | |
| SCHEMBL25479216 | 0.87 | CA14 (0.42) | CHRNB2CHRNA4CA14GBA1HDAC6 | |
| SCHEMBL18257000 | 0.87 | CA14 (0.42) | CHRNB2CHRNA4CA14GBA1HDAC6 | |
| SCHEMBL7783463 | 0.87 | HDAC6 (0.38) | CA14GBA1HDAC6HDAC1HDAC2 | |
| SCHEMBL19865535 | 0.87 | GBA1 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA4CA14 | |
| SCHEMBL10260946 | 0.86 | HDAC6 (0.40) | CHRNB2CHRNA4CA14GBA1HDAC6 | |
| SCHEMBL25970378 | 0.85 | CA14 (0.40) | CA14GBA1HDAC6HDAC1HDAC2 | |
| SCHEMBL13244217 | 0.84 | GBA1 (0.34) | CA14GBA1HDAC6HDAC1HDAC2 | |
| SCHEMBL20235037 | 0.84 | MAPT (0.43) | CA14GBA1HDAC6HDAC1HDAC2 | |
| SCHEMBL21871862 | 0.83 | GBA1 (0.35) | CA14GBA1HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240309005-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 | THRYV THERAPEUTICS INC. (CA) | 2024-09-19 | — | — | US | disclosed |
| WO-2024015055-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 AND TREATMENT OF CANCER | THRYV THERAPEUTICS INC. (CA) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024011307-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 AND TREATMENT OF CANCER | THRYV THERAPEUTICS INC. (CA) | 2024-01-18 | — | — | WO | disclosed |
| EP-4277905-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 | THRYV Therapeutics Inc. (CA) | 2023-11-22 | — | — | EP | disclosed |
| CN-117062817-A | Pyrazolo [3,4-D ] pyrimidin-6-yl-sulfonamide derivatives for SGK-1 inhibition | 斯瑞福治疗股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| EP-4178958-A1 | MACROCYCLES AND THEIR USE | Blossomhill Therapeutics, Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| WO-2022150911-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 | THERAPEUTIQUE QTL INC. (CA) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022011123-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| US-10682418-B2 | Polymer-sunitinib conjugates | NEKTAR THERAPEUTICS (US) | 2020-06-16 | — | — | US | disclosed |
| US-20180043028-A1 | POLYMER-SUNITINIB CONJUGATES | NEKTAR THERAPEUTICS | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240309005-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 | PGK1, SGK1, PGK2 | CHRNB2 4585/4885CHRNB4 4558/4885CHRNA3 4582/4885 |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | VHL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DLD | CHRNB2 4783/4885CHRNB4 4849/4885CHRNA3 4739/4885 |
| US-20180043028-A1 | POLYMER-SUNITINIB CONJUGATES | FLT4, TEK, TIE1 | CHRNB2 4872/4885CHRNB4 4869/4885CHRNA3 4845/4885 |
| US-10682418-B2 | Polymer-sunitinib conjugates | FLT4, TEK, TIE1 | CHRNB2 4872/4885CHRNB4 4869/4885CHRNA3 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.